LabPON Achieves 100 Percent Digital Diagnosis for Clinical Cases with Philips

Philips Royal Philips (NYSE: PHG, AEX: PHIA) announced that the Netherlands-based LabPON has become the first clinical pathology laboratory in the world to have transitioned completely to digital diagnosis. With this shift, all clinical histology cases are now being assessed and diagnosed digitally with the Philips IntelliSite Pathology Solution instead of with a microscope, leading to improved laboratory efficiency, quality and service levels.

Pathology plays a critical role in disease detection, particularly with cancer diagnosis. Suspicious tissue samples are investigated through a microscope to determine if the tissue is malignant and consequently guides treatment decisions. As the largest pathology laboratory in the Netherlands, LabPON is consulted on more than 54,000 histological cases each year, which translates to more than 300,000 slides of human tissue. Each of these slides needs to be prepared, analyzed, diagnosed, reported and archived every year. Digitizing these images eases collaboration across sites, reducing costs. Improved cooperation also allows access to specialists, engendering multidisciplinary discussions to share expertise and knowledge to ultimately come to a better diagnosis for the patient.

"Transitioning our entire workflow to digital processes demonstrates our commitment to ensuring our patients and clinical colleagues receive the fastest, most effective and best informed diagnoses possible," said Alexi Baidoshvili, pathologist, LabPON. "The revolutionary pathology solution from Philips provides us the images and speed we need, and their IT product seamlessly integrates with existing lab systems, while improving collaboration. Philips' understanding of the needs of our pathologists has ensured their adoption and improved throughput."

"Digitization of pathology offers a new way to tackle some of the growing challenges in the field, like higher cancer rates and the massive quantity of slides generated annually at these sites," said Russell Granzow, General Manager, Philips Digital Pathology Solutions. "LabPON's success in moving to entirely digital workflows emphasizes the role our solutions are playing across the health continuum to enable definitive diagnosis and improved patient care."

LabPON, which has 17 pathologists and a total of 115 employees, is also partnering with two other major labs in the Netherlands - University Medical Center Groningen and Isala Klinieken in Zwolle - to form a virtual network that allows 49 pathologists to collaborate easily, share cases in a secured way, and directly set up consultations.

LabPON has been working toward this milestone with Philips since 2012, using a structured change management approach to full digital adoption by its pathologists. This makes LabPON and Philips a valuable resource seeking to help others in their digital transformation.

Philips is an innovator in health technologies to enhance patient care and cure from healthy living and prevention, to diagnosis, treatment and home care. The company is a pioneer and leader in digital pathology, with a fast growing installed base and innovation partnerships with leading healthcare providers across the globe.

Philips IntelliSite Pathology Solution is a new platform to help pathologists make that next step in workflow improvement and accelerate knowledge sharing between care providers. Digital pathology will open up new ways to get more information from tissue samples and connect with other diagnostic modalities. Philips IntelliSite Pathology Solution is CE marked for primary diagnostics in the EU and Health Canada. In the U.S., Philips IntelliSite Pathology Solution is cleared by FDA for diagnostic use in the evaluation of HER2 expression in breast cancer and is offered for research use (RUO).

Related news articles:

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

About LabPON
LabPON represents Laboratory Pathology East Netherlands and is located in in Hengelo, The Netherlands. LabPON carries out pathological examinations for hospitals and general practices in the region Twente and Achterhoek- East. As the largest pathology laboratory in the Netherlands, it is committed to excel in speed and quality to the benefit of each patient. The development of digital pathology will certainly contribute to this.

Most Popular Now

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...